Exane BNP Paribas upgraded Genmab (GMAB) to Neutral from Underperform with a DKK 1,500 price target. The firm sees a “reasonable” valuation at ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

The Allegations: Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo’s Phase 3 CagriSema Study on Obesity According to the complaint ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

In December, the share price fell by around 20% following the announcement of trial results for their next-generation weight loss drug, CagriSema. On Friday, the stock, however, saw a much-needed ...

COURT: D.N.J. TRACK DOCKET: No. 2:25-cv-00713 (Bloomberg Law subscription) A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...

A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot CagriSema caused economic damage after patients lost less weight using the ...

While the initial market reaction to Novo’s more enhanced CagriSema weight loss treatment was negative, we believe this is a more potent formulation that can better compete with Lilly’s suite.

See the 10 stocks » On Friday morning, Novo Nordisk unveiled the latest results from a clinical trial of CagriSema, an investigational drug leveraging the foundational semaglutide molecule used ...

Investors had dumped Novo shares in late December when data on a highly touted experimental Novo weight-loss shot called CagriSema fell far short of the expectations the company had set.